Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LY3871801 · R-552

Small molecule · developed by Eli Lilly and Company

Phase 2 Most advanced trial (none active)
1 Registered trials

What is LY3871801?

LY3871801 is a drug studied in rheumatoid arthritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
R-552
Drug type
Small molecule
Therapy area
Immunology
Developer
Eli Lilly and Company
In trials of
RIGL
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
S53J4A7ME4

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05848258 Phase 2 Rheumatoid Arthritis Completed RIGL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Rheumatoid Arthritis

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.